Medtronic reports real-world data on Reactive ATP therapy
Medtronic announced that, according to a real-world analysis of nearly 8,800 patients presented at EHRA EUROPACE-CARDIOSTIM 2017, its Reactive ATP therapy slows the progression of AF in patients with implanted cardiac devices. Specifically, the retrospective analysis assessed pacemaker, ICD and CRT device data from 8,798 patients followed by the Medtronic CareLink remote monitoring system. Reactive ATP therapy was associated with a statistically significant decrease in AF events compared to a matched control group. Most notably, the Reactive ATP patient group experienced a 38 percent reduction in persistent AF events. This benefit was observed across patient age, sex, and device type.